Programmed Cell Death-1 (PD1, PD-1)
Showing 26 - 50 of >10,000
Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)
Recruiting
- Donafenib
- Donafenib, PD-1
- TACE
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University,
Mar 4, 2022
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)
Recruiting
- Relapsed Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Nivolumab
- Pembrolizumab
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022
EBV Infection Trial in Beijing (PD1 antibody, lenalidomide)
Recruiting
- EBV Infection
- PD1 antibody
- lenalidomide
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Jan 4, 2022
Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)
Recruiting
- Urothelial Carcinoma
- Zilovertamab vedotin
-
Cleveland, Ohio
- +11 more
Jan 25, 2023
NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1
Not yet recruiting
- Non-Small Cell Lung Cancer
- Capsulized Fecal Microbiota Transplant
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Aug 12, 2021
Lichen Planus Trial in Cairo (Skin Biopsy)
Not yet recruiting
- Lichen Planus
- Skin Biopsy
-
Cairo, EgyptCairo University
May 14, 2021
Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)
Recruiting
- Peripheral T-cell Lymphoma
- PD-1 antibody+ HDAC inhibitor
-
Shanghai, Shanghai, ChinaDongmei Ji
Dec 3, 2021
NSCLC Trial (Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Drug-eluting beads bronchial arterial chemoembolization
- Programmed Cell Death Protein 1 Inhibitor
- (no location specified)
Feb 17, 2022
Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)
Recruiting
- Relapsed/ Refractory Multiple Myeloma
- Talquetamab
- +2 more
-
Denver, Colorado
- +19 more
Jan 27, 2023
Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma Trial in New York (Nivolumab, Atezolizumab, Radiation &
Terminated
- Metastatic Renal Cell Carcinoma
- Metastatic Urothelial Carcinoma
- Nivolumab
- +3 more
-
New York, New YorkWeill Cornell Medicine - New York Presbyterian Hospital
Aug 26, 2021
EBV Infection Trial in Suzhou (PD-1 mAb)
Recruiting
- EBV Infection
- PD-1 monoclonal antibody
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 1, 2021
Safety of ICIs and TKIs Therapy for HCC
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Lenvatinib Oral Product
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Jun 11, 2022
Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent
Recruiting
- Cervical Carcinoma
- +8 more
- Camrelizumab plus Concurrent chemoradiotherapy
-
Beijing, Beijing, ChinaLei Li
Apr 5, 2022
Plaque, Atherosclerotic, Immune Checkpoint Inhibitors, Programmed Cell Death Protein 1 Inhibitor Trial in Hangzhou (PD-1 immune
Recruiting
- Plaque, Atherosclerotic
- +4 more
- PD-1 immune checkpoint blockades
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital of Zhejiang University, School of
Nov 16, 2021
Recurrent/ Advanced Stage Endometrial Cancer Patients Trial in Guangzhou (Niraparib in Combination With Anti-PD1 Antibody)
Recruiting
- Recurrent/ Advanced Stage Endometrial Cancer Patients
- Niraparib in Combination With Anti-PD1 Antibody
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Centre
Aug 20, 2021
Advanced or Unresectable Melanoma Progressing After PD1 Blockade Trial in Norway, United States (ONCOS-102, Cyclophosphamide,
Completed
- Advanced or Unresectable Melanoma Progressing After PD1 Blockade
- ONCOS-102
- +2 more
-
Baltimore, Maryland
- +3 more
Oct 11, 2021
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in
Suspended
- Anatomic Stage IV Breast Cancer AJCC v8
- +8 more
- Atezolizumab
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
May 23, 2022
Multiple Myeloma Trial in Belgium, Israel, Spain (Daratumumab, JNJ-63723283)
Completed
- Multiple Myeloma
-
Antwerpen, Belgium
- +12 more
Dec 1, 2022
Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal
Not yet recruiting
- Nasopharyngeal and Hypopharyngeal Carcinoma
- immunohistochemical
-
Sohag, EgyptSohag University Hospital
Oct 23, 2022
Regorafenib Plus Programmed Cell Death-1 Inhibitors in Advanced
Active, not recruiting
- Advanced Colorectal Carcinoma
- Regorafenib
- +6 more
-
Beijing, ChinaDepartment of Medical Oncology, Peking Union Medical College Hos
Feb 23, 2021
NSCLC Trial (biological, drug, radiation)
Withdrawn
- Non-small Cell Lung Cancer
- avelumab
- +21 more
- (no location specified)
Mar 17, 2021
Melanoma Trial (biological, drug, radiation)
Withdrawn
- Melanoma
- Avelumab
- +17 more
- (no location specified)
Mar 17, 2021